Lymphangioma
Lymphangioma is a rare condition characterized by abnormal growths of lymphatic vessels, often associated with genetic mutations like PIK3CA. These malformations can lead to swelling and other complications depending on their location.
Alpelisib for Lymphatic Malformations with PIK3CA Mutation
We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have a confirmed diagnosis of symptomatic Lymphatic Malformation (LyM)?
- Do you have type I diabetes or uncontrolled type II diabetes?
- Have you had previous treatment with alpelisib or any other PI3K inhibitors for more than 2 weeks?
- Are you currently receiving any non-drug therapies like surgery or sclerotherapy?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Byl719
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Cliniques Universitaires Saint-Luc
#3001: Centre de malformations vasculaires congenitales
Sint-Stevens-Woluwe, Belgium
Pellegrin Hospital
3102: Unité de Dermatologie Pédiatrique
Bordeaux, France
Hospices Civils De Lyon
3101: Hôpital Femme Mère Enfant Département Médical
Bron, France
Sponsor: Novartis Pharma AG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.